ILiAD Biotechnologies is a privately held, clinical stage biotechnology company dedicated to the prevention and treatment of human disease caused by Bordetella pertussis. The company is developing and acquiring key technologies, working with leading scientists to overcome the limitations of current vaccines, investigating the impact of B. pertussis in a range of human disease, and is focused on validating its proprietary vaccines in human clinical trials.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/06/22 | $42,800,000 | Series D |
Knott Partners | undisclosed |
